|
US7329758B1
(en)
|
1999-05-24 |
2008-02-12 |
California Institute Of Technology |
Imidazolidine-based metal carbene metathesis catalysts
|
|
CA2432578C
(en)
|
2001-01-02 |
2008-04-01 |
F. Hoffmann-La Roche Ag |
Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
|
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
EP2385053B1
(en)
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
|
US20080051387A1
(en)
|
2006-06-09 |
2008-02-28 |
Yuelian Xu |
Tetrahydropyrido[3,4-d]pyrimidines and related analogues
|
|
US9259426B2
(en)
|
2006-07-20 |
2016-02-16 |
Gilead Sciences, Inc. |
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
|
KR101438245B1
(ko)
|
2006-08-23 |
2014-09-04 |
쿠도스 파마슈티칼스 리미티드 |
Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
|
|
CA2673299C
(en)
|
2006-12-21 |
2016-04-12 |
Sloan-Kettering Institute For Cancer Research |
Pyridazinone compounds for the treatment of proliferative diseases
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
EP2209775A1
(en)
|
2007-10-09 |
2010-07-28 |
UCB Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
AR073354A1
(es)
|
2008-07-31 |
2010-11-03 |
Genentech Inc |
Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
WO2010103094A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
US8591943B2
(en)
|
2009-04-09 |
2013-11-26 |
Merck Sharp & Dohme Corp. |
Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
|
|
WO2010120996A1
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
US8455476B2
(en)
|
2009-04-22 |
2013-06-04 |
Janssen Pharmaceutica, Nv |
Azetidinyl diamides as monoacylglycerol lipase inhibitors
|
|
EP2518064A1
(en)
|
2009-12-25 |
2012-10-31 |
Mochida Pharmaceutical Co., Ltd. |
Novel aryl urea derivative
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
US9227971B2
(en)
|
2010-01-19 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
|
US20150361120A1
(en)
|
2010-03-31 |
2015-12-17 |
Chengzhi Zhang |
MACROLIDE INHIBITORS OF mTOR
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
JP2013529212A
(ja)
|
2010-05-19 |
2013-07-18 |
エクスカバリー ホールディング カンパニー，エルエルシー |
ｍＴＯＲ選択的キナーゼ阻害剤
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
AU2011332859A1
(en)
|
2010-11-24 |
2013-06-20 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mTOR and methods of their use and manufacture
|
|
JP2014510122A
(ja)
|
2011-04-04 |
2014-04-24 |
セルゾーム リミテッド |
ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
|
|
US8901142B2
(en)
|
2011-07-26 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds as mTOR inhibitors
|
|
ES2609606T3
(es)
|
2011-09-21 |
2017-04-21 |
Cellzome Limited |
Derivados de urea y carbamato de 2-morfolino-1,3,5-triazina como inhibidores de mTOR para el tratamiento de enfermedades inmunológicas o proliferativas
|
|
BR112014008241A2
(pt)
|
2011-10-07 |
2017-04-18 |
Cellzome Ltd |
composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
|
|
CA2856803A1
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
FR2986232B1
(fr)
|
2012-01-26 |
2014-02-14 |
Sanofi Sa |
Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
WO2014011973A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
|
|
PL2880014T3
(pl)
|
2012-08-06 |
2017-10-31 |
Pitney Pharmaceuticals Pty Ltd |
Związki do leczenia chorób związanych ze szlakiem mTOR
|
|
CN113201073A
(zh)
*
|
2012-11-21 |
2021-08-03 |
詹森生物科技公司 |
双特异性EGFR/c-Met抗体
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
JP6473133B2
(ja)
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓｇ１２ｃの共有結合性阻害剤
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
AU2014331794C1
(en)
|
2013-10-10 |
2019-09-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C
|
|
CN105899232A
(zh)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
用于增强免疫应答的mTOR抑制剂
|
|
MA40074A
(fr)
|
2014-05-30 |
2015-12-03 |
Univ Columbia |
Composés liant ras multivalents
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
JO3556B1
(ar)
*
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
|
CN112353938A
(zh)
*
|
2015-02-05 |
2021-02-12 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
US10017540B2
(en)
|
2015-03-11 |
2018-07-10 |
California Institute Of Technology |
Cyclic peptide binder against oncogenic K-Ras
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
WO2016172692A1
(en)
|
2015-04-24 |
2016-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Mutant kras inhibitors
|
|
BR112017023821A2
(pt)
|
2015-05-06 |
2018-07-31 |
Leidos Biomedical Res Inc |
moduladores de k-ras
|
|
WO2016201481A1
(en)
|
2015-06-15 |
2016-12-22 |
Newsouth Innovations Pty Limited |
Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6877414B2
(ja)
|
2015-09-24 |
2021-05-26 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｋｒａｓ発現のモジュレーター
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
JP6953400B2
(ja)
|
2015-10-22 |
2021-10-27 |
ザ スクリプス リサーチ インスティテュート |
システイン反応性プローブとその使用
|
|
WO2017080980A1
(en)
|
2015-11-09 |
2017-05-18 |
Astrazeneca Ab |
Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
|
|
WO2017079864A1
(en)
|
2015-11-12 |
2017-05-18 |
Hangzhou Yier Biotech Co., Ltd. |
Treatment of cancers related to chronically active ras
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
JP7039489B2
(ja)
|
2016-05-18 |
2022-03-22 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
MX2019006296A
(es)
|
2016-11-30 |
2019-11-12 |
Bantam Pharmaceutical Llc |
Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
|
|
AU2017366901B2
(en)
|
2016-11-30 |
2022-09-29 |
Bantam Pharmaceutical, Llc |
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
|
|
BR112019012263A2
(pt)
|
2016-12-15 |
2020-01-28 |
The Regents Of The University Of California |
composições e métodos para tratar câncer
|
|
WO2018119183A2
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7219218B2
(ja)
|
2016-12-22 |
2023-02-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
|
|
JP7108631B2
(ja)
|
2017-01-06 |
2022-07-28 |
パルヴェラ セラピューティクス、インク． |
ｍＴＯＲ阻害剤の無水組成物およびその使用方法
|
|
US10344026B2
(en)
|
2017-01-18 |
2019-07-09 |
Nantbio, Inc. |
Compositions and methods of targeting mutant K-ras
|
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
BR112019021899A2
(pt)
|
2017-04-20 |
2020-08-18 |
The Regents Of The University Of California |
moduladores de k-ras
|
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
HRP20230377T1
(hr)
|
2017-11-15 |
2023-06-23 |
Mirati Therapeutics, Inc. |
Inhibitori mutacije kras g12c
|
|
US11545829B2
(en)
|
2018-07-31 |
2023-01-03 |
Honda Motor Co., Ltd. |
Power prediction system, power prediction device, power prediction method, program, and storage medium
|
|
CN113038342B
(zh)
|
2018-09-30 |
2022-10-14 |
荣耀终端有限公司 |
音频播放电路和终端
|
|
CN111193490B
(zh)
|
2018-11-14 |
2025-05-13 |
天津大学 |
散热结构、带散热结构的体声波谐振器、滤波器和电子设备
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US20220193242A1
(en)
|
2019-02-07 |
2022-06-23 |
The Regents Of The University Of California |
Immunophilin-dependent inhibitors and uses thereof
|
|
EP3924687A4
(en)
|
2019-02-11 |
2022-11-02 |
Mesomat Inc. |
SENSING FIBERS FOR STRUCTURAL STRESS MONITORING
|
|
KR102747104B1
(ko)
|
2019-02-18 |
2024-12-27 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
|
|
WO2020172332A1
(en)
|
2019-02-20 |
2020-08-27 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for ras neoantigens and uses thereof
|
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
EP3931564A4
(en)
|
2019-02-26 |
2023-04-26 |
Cell Response, Inc. |
Methods for treating map3k8 positive cancers
|
|
WO2020177629A1
(zh)
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
ES3010507T3
(en)
|
2019-03-05 |
2025-04-03 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
AU2019432235B2
(en)
|
2019-03-05 |
2024-02-01 |
Questor Technology Inc. |
Gas incinerator system
|
|
US12448429B2
(en)
|
2019-03-06 |
2025-10-21 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
US20220160714A1
(en)
|
2019-03-22 |
2022-05-26 |
Icahn School Of Medicine At Mount Sinai |
Methods for treating colorectal cancer
|
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
AU2020254492A1
(en)
|
2019-03-29 |
2021-11-11 |
Kura Oncology, Inc. |
Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
|
|
KR102222693B1
(ko)
|
2019-04-04 |
2021-03-04 |
금정제약 주식회사 |
H-rev107 유래 펩타이드의 신규한 용도
|
|
US12528796B2
(en)
|
2019-04-15 |
2026-01-20 |
Tosk, Inc. |
Modulators of RAS GTPase
|
|
US20200335182A1
(en)
|
2019-04-16 |
2020-10-22 |
Uratim Ltd. |
Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
|
|
US20220251109A1
(en)
|
2019-04-28 |
2022-08-11 |
Genfleet Therapeutics (Shanghai) Inc. |
Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
|
|
MX2021013662A
(es)
|
2019-05-10 |
2022-03-11 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
|
|
EP3966207B1
(en)
|
2019-05-10 |
2023-11-01 |
Deciphera Pharmaceuticals, LLC |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
ES3025633T3
(en)
|
2019-05-13 |
2025-06-09 |
Novartis Ag |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
WO2020230091A1
(en)
|
2019-05-14 |
2020-11-19 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CN114096544B
(zh)
|
2019-05-20 |
2025-08-12 |
加州理工学院 |
Kras g12c抑制剂及其用途
|
|
CN118359609A
(zh)
|
2019-05-21 |
2024-07-19 |
益方生物科技(上海)股份有限公司 |
杂环化合物，其制备方法和用途
|
|
AU2020277398B2
(en)
|
2019-05-21 |
2026-01-29 |
Amgen Inc. |
Solid state forms
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
NZ782284A
(en)
|
2019-05-21 |
2024-11-29 |
Amgen Inc |
Solid state forms
|
|
AU2020289484A1
(en)
|
2019-06-07 |
2021-12-23 |
Emory University |
KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
|
|
AU2020291936A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
US20220304984A1
(en)
|
2019-06-12 |
2022-09-29 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
TW202115089A
(zh)
|
2019-07-01 |
2021-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
喹唑啉酮類衍生物、其製備方法及其在醫藥上的應用
|
|
MX2022001421A
(es)
|
2019-08-02 |
2022-06-08 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Compuesto tetracíclico, método de preparación y uso del mismo.
|
|
TWI752580B
(zh)
|
2019-08-07 |
2022-01-11 |
大陸商北京加科思新藥研發有限公司 |
Kras突變蛋白抑制劑
|
|
WO2021027943A1
(zh)
|
2019-08-14 |
2021-02-18 |
正大天晴药业集团南京顺欣制药有限公司 |
哒嗪酮并嘧啶类衍生物及其医药用途
|
|
CN112390797A
(zh)
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
US20220363681A1
(en)
|
2019-08-16 |
2022-11-17 |
Genfleet Therapeutics (Shanghai) Inc. |
Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
|
|
CN114286676A
(zh)
|
2019-08-22 |
2022-04-05 |
密歇根大学董事会 |
治疗kras相关癌症的方法
|
|
CN114269735B
(zh)
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
WO2021041671A1
(en)
|
2019-08-29 |
2021-03-04 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
CN112771053A
(zh)
|
2019-09-06 |
2021-05-07 |
伟迈可生物有限公司 |
基于生物标志物的治疗组合物
|
|
WO2021043322A1
(zh)
|
2019-09-06 |
2021-03-11 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
EP4028044A4
(en)
|
2019-09-10 |
2023-09-27 |
The Board of Trustees of the Leland Stanford Junior University |
Methods of treating kras mutant cancers
|
|
TW202124374A
(zh)
|
2019-09-13 |
2021-07-01 |
美商拜歐斯瑞克斯公司 |
Ras蛋白降解劑、其醫藥組合物及其治療應用
|
|
EP4031542B1
(en)
|
2019-09-18 |
2025-10-15 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras g12c mutant
|
|
CA3155066A1
(en)
|
2019-09-20 |
2021-03-25 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
US20230010886A1
(en)
|
2019-09-23 |
2023-01-12 |
Suzhou Puhe BioPharma Co., Ltd. |
Shp2 inhibitors and uses thereof
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
US20210094919A1
(en)
|
2019-09-25 |
2021-04-01 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
WO2021058018A1
(en)
|
2019-09-29 |
2021-04-01 |
Beigene, Ltd. |
Inhibitors of kras g12c
|
|
WO2021063346A1
(zh)
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
CN114555586B
(zh)
|
2019-10-10 |
2023-06-23 |
信达生物制药(苏州)有限公司 |
Krasg12c蛋白抑制剂及其制备方法和用途
|
|
JP6754125B1
(ja)
|
2019-10-15 |
2020-09-09 |
学校法人東京理科大学 |
Ｂｒａｐ２作用増強剤
|
|
WO2021076655A1
(en)
|
2019-10-15 |
2021-04-22 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
WO2021080359A1
(ko)
|
2019-10-23 |
2021-04-29 |
에스케이바이오팜 주식회사 |
바이사이클릭 화합물 및 이의 용도
|
|
EP4684786A3
(en)
|
2019-10-24 |
2026-04-08 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
CN114867726B
(zh)
|
2019-10-28 |
2023-11-28 |
默沙东有限责任公司 |
Kras g12c突变体的小分子抑制剂
|
|
PT4053118T
(pt)
|
2019-10-30 |
2024-12-05 |
Genfleet Therapeutics Shanghai Inc |
Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica deste
|
|
WO2021084765A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd |
4-aminobut-2-enamide derivatives and salts thereof
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
CN120699039A
(zh)
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
Ras抑制剂
|
|
WO2021088458A1
(en)
|
2019-11-04 |
2021-05-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
PE20221323A1
(es)
|
2019-11-07 |
2022-09-09 |
Chugai Pharmaceutical Co Ltd |
Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
|
|
CN112778301A
(zh)
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
WO2021093758A1
(zh)
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
US20230061083A1
(en)
|
2019-11-29 |
2023-03-02 |
Evopoint Biosciences Co., Ltd. |
Kras g12c inhibitor compound and use thereof
|
|
BR112022010254A2
(pt)
|
2019-12-02 |
2022-09-06 |
Shanghai Yingli Pharm Co Ltd |
Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
|
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
|
WO2021126799A1
(en)
|
2019-12-18 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
|
CA3165238A1
(en)
|
2019-12-19 |
2021-06-24 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
WO2021121371A1
(zh)
|
2019-12-19 |
2021-06-24 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
TR201920922A2
(tr)
|
2019-12-20 |
2020-06-22 |
Ankara Ueniversitesi |
3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN114929704B
(zh)
|
2019-12-27 |
2024-07-23 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉化合物
|
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
|
TWI770760B
(zh)
|
2020-01-08 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
螺環四氫喹唑啉
|
|
US20210269434A1
(en)
|
2020-01-10 |
2021-09-02 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
CN115175908B
(zh)
|
2020-01-13 |
2024-07-23 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
KR102396930B1
(ko)
|
2020-01-15 |
2022-05-12 |
한국과학기술연구원 |
피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
KR102382613B1
(ko)
|
2020-01-15 |
2022-04-06 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
WO2021147965A1
(zh)
|
2020-01-21 |
2021-07-29 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
EP4077328A4
(en)
|
2020-02-20 |
2023-11-29 |
Beta Pharma, Inc. |
PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS
|
|
TW202140450A
(zh)
|
2020-02-24 |
2021-11-01 |
大陸商泰勵生物科技（上海）有限公司 |
用於癌症治療的ｋｒａｓ抑制劑
|
|
CN114845997B
(zh)
|
2020-02-24 |
2024-03-29 |
上海喆邺生物科技有限公司 |
芳香类化合物及其在制备抗肿瘤药物中的应用
|
|
US20210292330A1
(en)
|
2020-02-28 |
2021-09-23 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
|
WO2021175199A1
(zh)
|
2020-03-02 |
2021-09-10 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
|
KR20210111711A
(ko)
|
2020-03-03 |
2021-09-13 |
웰마커바이오 주식회사 |
Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
|
|
MX2022010977A
(es)
|
2020-03-05 |
2022-12-02 |
Univ Michigan Regents |
Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
|
|
CA3172812A1
(en)
|
2020-03-05 |
2021-09-10 |
The Regents Of The University Of Michigan |
Inhibitors of egfr, kras, braf, and other targets and use of the same
|
|
KR102822517B1
(ko)
|
2020-03-12 |
2025-06-19 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
피리미도헤테로사이클릭 화합물 및 이의 응용
|
|
WO2021185233A1
(en)
|
2020-03-17 |
2021-09-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
CA3170068A1
(en)
|
2020-03-25 |
2021-09-30 |
Yuli Xie |
Spiro ring-containing quinazoline compound
|
|
AU2021248363B2
(en)
|
2020-04-03 |
2024-02-15 |
Medshine Discovery Inc. |
Octahydropyrazinodiazanaphthyridine dione compounds
|
|
US20220370416A1
(en)
|
2020-04-06 |
2022-11-24 |
Arvinas Operations, Inc. |
Compounds and methods for targeted degradation of kras
|
|
WO2021203768A1
(zh)
|
2020-04-08 |
2021-10-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并二环类衍生物、其制备方法及其在医药上的应用
|
|
CA3179692A1
(en)
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
EP4138875A4
(en)
|
2020-04-23 |
2024-08-28 |
The Regents of the University of California |
RAS INHIBITORS AND USES THEREOF
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2021218110A1
(zh)
|
2020-04-29 |
2021-11-04 |
上海凌达生物医药有限公司 |
一类苯并噻唑基联芳基类化合物、制备方法和用途
|
|
CN115135636B
(zh)
|
2020-04-29 |
2024-08-23 |
北京泰德制药股份有限公司 |
喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
CN116194456B
(zh)
|
2020-04-30 |
2025-08-29 |
上海科州药物股份有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
WO2021236475A1
(en)
|
2020-05-18 |
2021-11-25 |
Asinex Corporation |
Compounds that inhibit asparagine synthetase and their methods of use
|
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物，其製法與醫藥上的用途
|
|
US20230210852A1
(en)
|
2020-05-29 |
2023-07-06 |
Syros Pharmaceuticals, Inc. |
Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
|
|
WO2021245055A1
(en)
|
2020-06-02 |
2021-12-09 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
EP4161934A1
(en)
|
2020-06-04 |
2023-04-12 |
Antengene Discovery Limited |
Inhibitors of kras g12c protein and uses thereof
|
|
MX2022015253A
(es)
|
2020-06-04 |
2023-03-14 |
Pillai Universal Llc |
Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer.
|
|
US20230026856A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
US20230023009A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
|
WO2021249563A1
(zh)
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
EP4168414A1
(en)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
|
WO2022002102A1
(en)
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
EP4182313A4
(en)
|
2020-07-16 |
2024-10-09 |
Mirati Therapeutics, Inc. |
KRAS-G12D INHIBITORS
|
|
TW202214608A
(zh)
|
2020-07-20 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用
|
|
CN115052870B
(zh)
|
2020-08-02 |
2024-02-20 |
上海喆邺生物科技有限公司 |
一种芳香类化合物及其在抗肿瘤药物中的应用
|
|
EP4192585A4
(en)
|
2020-08-04 |
2024-08-21 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022028492A1
(en)
|
2020-08-05 |
2022-02-10 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
|
WO2022036176A1
(en)
|
2020-08-13 |
2022-02-17 |
Albert Einstein College Of Medicine |
N-cyclyl-sulfonamides useful for inhibiting raf
|